Anzeige
Mehr »
Login
Mittwoch, 29.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
16:01Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?
16:01FDA faults Biocon plant during preapproval review
16:01How influential are influencers? FDA plots study to measure power of Instagram celebs
DiPfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs
DiPfizer nixes multiple Bavencio tests, plus an early Inlyta-Keytruda combo trial
DiIncyte doubles down on atopic dermatitis push with trial win for JAK med Jakafi
DiAllergan unveils new Botox plant ahead of $63B AbbVie merger
DiJ&J CEO on the stand: Gorsky faces questions about well-timed stock trade, talc testing
DiShkreli faces new FTC, N.Y. crackdown for allegedly thwarting Daraprim generics
DiJ&J's ketamine depression drug Spravato spurned by England's influential cost watchdogs
MoMerck KGaA antes up €250M to bridge R&D with manufacturing
MoFDA faults Biocon's biosimilars plant during preapproval review
MoEli Lilly, Incyte's Olumiant notches another atopic dermatitis win. But can it fight Dupixent?
MoKrystal Biotech investing up to $90M on facility for its gene therapies
MoChina repurposes AbbVie HIV drug as Big Pharma rallies to combat deadly coronavirus
MoNew sickle cell drugs from Novartis, GBT need big discounts: ICER draft
MoAstraZeneca's Brilinta fends off repeat strokes better than solo aspirin, trial shows
MoFiercePharmaPolitics-PhRMA, BIO jack up lobbying spend as political squeeze intensifies
MoAbbVie, Allergan sell 3 drugs to win U.S. antitrust clearance-and send AstraZeneca, Nestlé into new realms
MoCall for FDA to withdraw preterm birth drug divides doctors and insurers
FrNICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
FrPfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%
FrRoche's Tecentriq flops in postsurgery muscle-invasive bladder cancer
FrInsys founder Kapoor gets 5.5 years in prison for role in Subsys kickback scheme
FrEpizyme scores FDA nod for rare cancer med Tazverik, but prices it for a future indication: analyst